Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy-Reference-Cited by-同舟云学术

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Published:2019-11 Issue:6 Volume:2 Page:670-676
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Thang Sue Ping,Violet John,Sandhu Shahneen,Iravani Amir,Akhurst Tim,Kong Grace,Ravi Kumar Aravind,Murphy Declan G.,Williams Scott G.,Hicks Rodney J.,Hofman Michael S.

Publisher

Elsevier BV

Subject

Urology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference31 articles.

1. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019);James;Eur Urol,2015

2. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study;Beer;Eur Urol,2017

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial);Radiology;2024-08-01

2. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer;Nature Reviews Urology;2024-07-08

3. From biology to the clinic — exploring liver metastasis in prostate cancer;Nature Reviews Urology;2024-04-26

4. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers;Cancer Treatment Reviews;2024-04

5. Clinical Positron Emission Tomography/Computed Tomography;PET Clinics;2024-04